|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
suspension
oral tablet
|
|
gptkbp:approves
|
gptkb:1973
|
|
gptkbp:atccode
|
J01 EE01
|
|
gptkbp:available_in
|
liquid form
tablet form
|
|
gptkbp:available_on
|
generic drug
|
|
gptkbp:brand
|
gptkb:Bactrim_DS
gptkb:Septra_DS
|
|
gptkbp:casnumber
|
804-75-5
|
|
gptkbp:chemical_formula
|
C18 H20 N4 O3 S
|
|
gptkbp:clinical_trial
|
Phase IV
|
|
gptkbp:combination_of
|
gptkb:sulfamethoxazole
gptkb:trimethoprim
|
|
gptkbp:contraindication
|
pregnancy
renal impairment
|
|
gptkbp:developed_by
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:dosage_form
|
160 mg trimethoprim and 800 mg sulfamethoxazole
one tablet every 12 hours
|
|
gptkbp:duration
|
7 to 14 days
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
trimethoprim-sulfamethoxazole
|
|
gptkbp:interacts_with
|
gptkb:methotrexate
gptkb:phenytoin
gptkb:warfarin
|
|
gptkbp:lifespan
|
8 to 10 hours
|
|
gptkbp:marketed_as
|
gptkb:Bactrim
gptkb:Septra
|
|
gptkbp:mechanism_of_action
|
inhibits bacterial folic acid synthesis
|
|
gptkbp:name
|
Essential Medicines
|
|
gptkbp:prescribed_for
|
gptkb:pneumocystis_pneumonia
bronchitis
otitis media
urinary tract infections
traveler's diarrhea
|
|
gptkbp:safety
|
Category C
|
|
gptkbp:side_effect
|
dizziness
fatigue
headache
nausea
vomiting
diarrhea
rash
loss of appetite
|
|
gptkbp:storage
|
room temperature
away from moisture
|
|
gptkbp:suitable_for
|
patients with liver disease
infants under 2 months
patients with G6 PD deficiency
|
|
gptkbp:used_for
|
bacterial infections
|
|
gptkbp:bfsParent
|
gptkb:Trypanosoma
gptkb:pneumocystis_pneumonia
gptkb:Pneumocystis_pneumonia
|
|
gptkbp:bfsLayer
|
5
|